NeuroPace (NPCE) Q1 2026: RNS System Grows 20% as AI Roadmap, IGE Expansion Drive Guidance Lift
NeuroPace posted 20% RNS revenue growth and raised its 2026 outlook, driven by robust prescriber expansion, accelerating patient funnel, and advancing AI-enabled clinical tools. The company’s mid-year IGE FDA decision and reimbursement ramp represent the next catalysts, while core epilepsy center penetration and repeat replacement cycles continue to mature. Investors should watch for execution on AI launches, payer adoption, and the cadence of new indications as durable growth levers.
Summary
- Patient Pipeline Surge: All-time highs in active prescribers and patient funnel signal accelerating adoption momentum.
- AI Platform Moves: Early validation of proprietary EEG models and ECOG Assistant position NPCE for workflow and outcome differentiation.
- IGE Indication Catalyst: Mid-year FDA decision and payer coverage expansion are set to define the next growth phase.
Business Overview
NeuroPace develops and commercializes the RNS System, a responsive neurostimulation device for drug-resistant epilepsy, generating revenue from device sales, service agreements, and data collaborations. The company’s core business centers on adult focal epilepsy, with expansion efforts targeting idiopathic generalized epilepsy (IGE), pediatric, and LGS (Lennox-Gastaut Syndrome) populations. Its RNS platform leverages a proprietary intracranial EEG dataset, supporting both device-based therapy and emerging AI-enabled clinical tools.
Performance Analysis
NeuroPace delivered 20% year-over-year RNS system revenue growth, driven by deepening penetration at level four epilepsy centers and a record patient pipeline. The company’s commercial execution has translated into new highs for active prescribers and account engagement, while community referral pathways are increasingly supplementing core center growth. Service revenue, though still a small contributor, benefited from new data collaboration partnerships.
Gross margin expanded on an underlying basis, aided by favorable pricing dynamics and product mix, while operating expense growth was held below revenue growth, demonstrating improving operating leverage. Sales and marketing investments continue, with headcount and incentive structure changes designed to sustain funnel velocity and procedural consistency. Replacement cycle revenue is still nascent but expected to become a recurring stream as RNS320 devices age.
- Commercial Team Productivity: Investments in sales force and nurse navigators are showing early impact in pipeline conversion and patient throughput.
- Pricing Tailwind: Consistent low-single-digit price increases are recurring, with volume as the dominant growth driver.
- Operating Discipline: R&D and G&A expenses remain tightly managed, supporting improved adjusted EBITDA loss guidance.
The company’s raised full-year outlook reflects both greater RNS visibility and incremental service revenue, while IGE expansion remains excluded until approval and payer coverage are secured.
Executive Commentary
"The majority of growth continues to be driven by level four comprehensive epilepsy centers, which remain the core of our commercial focus. In addition, we continue to see encouraging trends in the front end of the patient funnel with the rate of new patients being added to the pipeline continuing to accelerate."
Joel Becker, Chief Executive Officer
"Non-GAAP operating expense growth of approximately 10% in the quarter remained meaningfully below our revenue growth of 20%, again, demonstrating underlying operating leverage as we scale."
Patrick Williams, Chief Financial Officer
Strategic Positioning
1. Core Market Penetration and Referral Expansion
Level four epilepsy centers remain the primary growth engine, with new prescribers and deeper utilization supporting recurring procedure volume. The company’s Project CARE initiative and community outreach are building durable referral networks, critical for future indication expansions and broader patient access.
2. AI-Enabled Product Differentiation
NeuroPace’s investment in AI tools, including the ECOG Assistant and a multimodal foundational EEG model, leverages its unique longitudinal dataset from over 8,000 implants. These tools are designed to lower adoption barriers for new clinicians, improve workflow efficiency, and enable personalized therapy, positioning the RNS platform for sustained clinical leadership.
3. Indication Expansion and Clinical Evidence Leadership
The pending IGE indication, supported by robust Nautilus study data, represents a significant addressable market unlock. The company’s real-world evidence strategy for pediatrics and ongoing LGS trials further extend the clinical and commercial runway. Peer-reviewed publications and FDA-monitored studies reinforce the RNS system’s long-term efficacy and safety.
4. Reimbursement and Payer Strategy
Recent positive reimbursement trends, including OPPS and physician fee schedule improvements, de-risk hospital adoption and support procedural economics. The company is proactively preparing for IGE coverage expansion, leveraging published data and external advisory support to accelerate payer uptake post-approval.
5. Operating Leverage and Capital Allocation
Disciplined expense management and targeted R&D investment underpin improving EBITDA trajectory. Commercial and R&D capital is being allocated to programs with the highest platform leverage and differentiation potential, while G&A infrastructure is scaling to support growth without overextending overhead.
Key Considerations
This quarter’s results highlight NeuroPace’s ability to sustain durable growth in its core market while laying the groundwork for future expansion through AI innovation and new indications. The company’s approach to capital allocation, payer engagement, and clinical evidence generation will determine the pace and magnitude of its next growth phase.
Key Considerations:
- Patient Funnel Acceleration: Record pipeline metrics and prescriber expansion point to robust near-term volume trends.
- AI Product Launch Execution: Timely approval and clinician adoption of ECOG Assistant are key to workflow leadership.
- IGE Indication Timing and Payer Uptake: FDA approval and speed of private payer coverage will drive revenue inflection.
- Replacement Cycle Maturation: Recurring revenue from device replacements is set to become a more material contributor beyond 2026.
- Expense Leverage Sustainability: Maintaining operating discipline as commercial and R&D investments scale will be critical for margin improvement.
Risks
The primary risks include delays or negative outcomes in FDA review for IGE, slower-than-expected payer policy adoption, and potential execution gaps in AI-enabled product rollout. Competitive dynamics in neuromodulation, evolving reimbursement frameworks, and the challenge of scaling community referral networks could also impact revenue trajectory and profitability. Management’s guidance explicitly excludes IGE contribution, reflecting an appropriately cautious stance on regulatory and coverage timing.
Forward Outlook
For Q2 2026, NeuroPace guided to:
- Continued double-digit RNS system growth, consistent with first-half seasonality patterns.
- AI ECOG Assistant submission and expected approval in Q2.
For full-year 2026, management raised guidance:
- Revenue range of $99 million to $101 million (from $98 million to $100 million).
- Adjusted EBITDA loss improved to $8.5 million to $9.5 million.
Management highlighted several factors that shape the outlook:
- Commercial investments will drive increasing productivity and leverage through 2026 and into 2027.
- IGE indication, if approved, will be incorporated into guidance only after reimbursement visibility improves.
Takeaways
NeuroPace’s Q1 results reinforce its position as a leading innovator in neuromodulation, with durable core growth, expanding clinical evidence, and a credible AI roadmap. The next phase hinges on successful IGE approval and payer adoption, with recurring replacement revenue and workflow differentiation as additional upside levers.
- Core Growth Endurance: Strong prescriber and patient funnel metrics underpin confidence in sustained RNS adoption and utilization.
- AI and Indication Expansion as Multipliers: Proprietary data and clinical innovation are set to drive competitive differentiation and open new markets.
- Execution Watchpoints: Investors should monitor AI tool launch cadence, IGE approval and coverage timing, and the maturation of replacement cycle revenue as the next inflection points.
Conclusion
NeuroPace enters mid-2026 with strong commercial momentum, prudent operating leverage, and an advancing product and clinical pipeline. The company’s ability to convert its AI and indication expansion initiatives into tangible growth will be the key determinant of its long-term value creation trajectory.
Industry Read-Through
NeuroPace’s results highlight a sector-wide shift toward data-driven, AI-enabled neuromodulation, with reimbursement frameworks and clinical evidence increasingly central to adoption. Competitors in epilepsy and broader neurostimulation markets should note the strategic importance of proprietary datasets, payer engagement, and referral network development. Positive reimbursement trends and the emergence of recurring replacement revenue streams may serve as a bellwether for similar device platforms, while the pace of AI tool adoption will likely separate clinical leaders from laggards in the coming cycles.